BRL Medicine Inc. is dedicated to becoming the world's leading Cell and Gene Therapeutic, with the mission of
BRL Medicine Inc. is dedicated to becoming the world's leading Cell and Gene Therapeutic, with the mission of
23+ Has applied for 125 invention patents at home and abroad Has five core technology platforms with independent intellectual property rights Relying on its strong technical strength and scientific research team in the field of gene editing and immunology, BRL Medicine is dedicated to the development...
商标名称 邦耀生物 BRL MEDICINE 国际分类 第05类-医药 商标状态 商标注册申请 申请/注册号 59937793 申请日期 2021-10-19 申请人名称(中文) 上海邦耀生物科技有限公司 申请人名称(英文) - 申请人地址(中文) 上海市闵行区元江路3699号12幢 申请人地址(英文) - 初审公告期号 - 初审公告日期 2022-03-06 注册...
BRL Medicine Inc 疾病领域得分 一眼洞穿机构专注的疾病领域 技术平台 公司药物应用最多的技术 靶点 公司最常开发的靶点 项与 上海邦耀生物科技有限公司 相关的临床试验 /Not yet recruiting Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia...
邦耀生物(BRL Medicine)近日宣布,其新一代同种异体通用型CAR-T疗法TyU19用于治疗自身免疫疾病的研究成果发布于国际顶级学术期刊《细胞》上。研究显示,TyU19在两周内使3名难治性自身免疫疾病患者的B细胞耗竭,并逆转了两名 - 药时代于20240717发布在抖音,已经收获了2.0
点击下方链接直达获取BRL-201最新研发进展。 靶向CD19 非病毒 PD1 定点整合 CAR-T 细胞(上海邦耀)(Non-viral PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells (BRL Medicine))-药物靶点:CD19_在研适应症:复发性B细胞淋巴瘤,难治性B细胞淋巴瘤_专利_临床_研发...
Brl Medicine Inc., Shanghai, ChinaYongXian HuBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaJiqin ZhangBRL Medicine Inc., Shanghai, Shanghai, ChinaMingming ZhangBone Marrow Transplantation Center, The First Affiliated Hospital, ...
Faculty of Medicine, University of Tokyo and affiliated hospitals. Patients were given 1. 6 g or 3.2g of BRL 28500 twice a day for 5 days by intravenous drip infusion or intravenous one shot injection. Overall clinical efficacy in... T Tominaga,H Kishi,T Niijima - 《Japanese Journal of...
这项早期的临床研究成果,于2022年8月4日发表在国际顶级医学学术期刊 Nature Medicine 上。 “此次BRL-101的1期临床试验首例成人重型地贫患者顺利治疗出院,使我们朝着为输血依赖型β-地贫患者带来一次性治愈疗法的目标又更进了一步,也让我们更加有信心加速该项多中心注册临床试验的研究进程。”邦耀生物CEO郑彪博士表示...